CD8A and neoplasm: Tumour‐infiltrating T cells, especially CD8+ T cells, which are the primary mediators of anti‐tumour cellular immunity, have been a central focus of immunotherapy for the treatment of cancer5 and contributed positively to anti‐tumour immunity in different types of cancers, including ESCC.6, 7